The researchers' analysis identified four subtypes--all very genetically different
The researchers performed a multi-platform analysis of genomic alterations and gene expression on tumor samples from 574 patients with diffuse large B-cell lymphoma. This analysis identified four prominent genetic subtypes that each share a group of genetic deviations. Patients with two of the subtypes, called BN2 and EZB, respond well to treatment, while those with the other two, MCD and N1, do not. Some of these subtypes can be found in both ABC (activated B-cell-like) and GCB (germinal center B-cell-like) subgroups, so a patient could, for example, have ABC (activated B-cell-like) diffuse large B-cell lymphoma, the gene expression profile with the lower survival rate, but the disease could also have the BN2 genetic subtype that responds well to chemotherapy.